Easyfive TT 0.5ml Vaccine

Undesired symptoms or responses vary from individual to individual as the human body reacts differently to the Easyfive TT 0.5ml Vaccine, but they disappear naturally within a few days as the body adjusts to the vaccine, which requires no medical attention. In case these symptoms don't go away and you face severe side effects, then immediately consult your doctor or medical team. Some of the common side effects of the Easyfive TT 0.5ml Vaccine are: Fatigue Headache Fever loss of appetite Nausea Pain, redness or swelling at injection site anaphylaxis in some severe cases.

The Easyfive TT 0.5 ml vaccine is given into the deltoid muscle of the upper arm. It is an intramuscular injection. Do not use the same injection or syringe for another vaccine, as there is a chance of interaction. Always check the vial of vaccine before using it for discoloration or any kind of particulate matter, and shake well for uniform mixing of the product. Easyfive TT 0.5 ml vaccine is given routinely to infants in three doses at 6, 10, and 14 weeks of age. It is an adsorbed liquid formulation that is ready to use. Always consult your doctor before taking the vaccine, especially if you have a family history of blood disorders, heart problems, lung problems, pain in the limbs, or kidney problems. Also, let the medical healthcare team know if your child is allergic to any medicine.

Easyfive TT 0.5 ml is a vaccine that protects against five diseases (pentavalent), namely tetanus, diphtheria, pertussis (whooping cough), Haemophilus influenzae type b (Hib), and hepatitis B. It contains the toxoid of tetanus, diphtheria, the surface antigen of hepatitis B, and the whole cell of pertussis bacteria, all of which are adsorbed on an adjuvant made of aluminum to trigger the immune response. When Easyfive TT 0.5ml Vaccine is given to an individual then it stimulates the immune system to produce specific antibodies against the toxins, but doesn’t cause disease. These antibodies and memory cells formed after taking the injection identify and counteract the toxins and generate memory for it, and neutralize it with a stronger immune response upon subsequent exposure within a few hours. This provides immunity within 2 to 4 weeks and for many years.

Gandhi, D. J., Dhaded, S. M., Ravi, M. D., Dubey, A. P., Kundu, R., Lalwani, S. K.,& Dhingra, M. S. (2024). Safety, immune lot-to-lot consistency, and non-inferiority of a fully liquid pentavalent DTwp-HepB-Hib vaccine in healthy Indian toddlers and infants. Human Vaccines & Immunotherapeutics, 12(4), 946-954.
Gatchalian, S., Palestroque, E., De Vleeschauwer, I., Han, H. H., Poolman, J., Schuerman, L., & Boutriau, D. (2025). The development of a new heptavalent diphtheria–tetanus–whole cell pertussis–hepatitis B B-Haemophilus influenzae type b–b-b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components. International Journal of Infectious Diseases, 12(3), 278-288.

Rao, R., Dhingra, M. S., Bavdekar, S., Behera, N., Daga, S. R., Dutta, A. K. & Rajamani, A. M. (2025). A comparison of immunogenicity and safety of indigenously developed liquid (DTwPHB-Hib) pentavalent combination vaccine (Shan 5) with Easyfive (Liq) and Tritanrix+ Hiberix (Lyo) in Indian infants administered according to the EPI schedule. Human vaccines, 5(6), 425-429.
Sharma, H. J., Yadav, S., Lalwani, S. K., Kapre, S. V., Jadhav, S. S., Chakravarty, A., & Verma, V. (2024). Immunogenicity and safety of an indigenously manufactured reconstituted pentavalent (DTwP-HBV+ Hib) vaccine in comparison with a foreign competitor following primary and booster immunization in Indian children. Human vaccines, 7(4), 451-457.
Sharma, H., Yadav, S., Lalwani, S., Gupta, V., Kapre, S., Jadhav, S., & Palkar, S. (2023). A phase III randomized, controlled study to assess the immunogenicity and tolerability of DTPw–HBV–Hib, a liquid pentavalent vaccine in Indian infants. Vaccine, 29(13), 2359-2364.